Loading asset research
Nanobiotix S.A. American Depositary Shares
NBTXNasdaq · USD · StocksQuote as of · Exchange session not verified$37.01
-1.57%
Today
NBTX
Loading 1D prices…
Market cap
$1.9B
Volume
93.8K
52w high
$57.1452w low
$9.32Company profile
Nanobiotix S.A. American Depositary Shares
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Paris, France, United States
Employees
100
Fiscal year end
1231
CIK
1760854
Session & valuation
Open$37.00
Previous close$37.60
Day high$37.70
Day low$36.43
30-day avg. volume158.2K
Outstanding shares48.4M
Diluted EPS-$0.50
Latest annual period
P/E (trailing)-74.02
P/E (forward)-108.74
Price / book-18.29
Beta0.57
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ZYMEZymeworks Inc. Common Stock | $1.9B | $106M | -76.56% | -$1.08 | -0.74% | Buy |
| STOKStoke Therapeutics Inc. Common Stock | $1.9B | $184.4M | -3.73% | -$0.12 | +0.26% | Buy |
| PRGOPerrigo Company plc Ordinary Shares | $1.9B | $4.3B | -33.51% | -$10.29 | +0.63% | Hold |
| GHRSGH Research PLC Ordinary Shares | $1.9B | $0.00 | — | -$0.79 | -0.84% | Buy |
| BHVNBiohaven Ltd. Common Shares | $1.9B | $0.00 | — | -$6.86 | -0.66% | Buy |